Balance Sheet
Consolidated
| IN CR | MAR 2025 | MAR 2024 | MAR 2023 | MAR 2022 | MAR 2021 | MAR 2020 |
|---|---|---|---|---|---|---|
| SOURCES OF FUNDS | ||||||
| Share Capital | 58.08 | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 |
| Share warrants and Outstandings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Reserve | 32,595.24 | 29,784.21 | 26,781.26 | 24,517.39 | 21,871.28 | 16,766.08 |
| Shareholder's Funds | 32,653.32 | 29,842.80 | 26,839.85 | 24,575.98 | 21,929.87 | 16,824.67 |
| Minority Interest | -6.39 | 8.00 | 12.00 | -1.93 | -0.88 | 0.14 |
| Secured Loans | 1,159.38 | 2,134.90 | 618.96 | 249.21 | 168.40 | 0.00 |
| Unsecured Loans | 402.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debts | 7,941.68 | 6,315.22 | 4,861.52 | 2,372.77 | 4,971.11 | 5,561.97 |
| Total Liabilities | 34,799.36 | 32,515.82 | 28,006.60 | 25,354.78 | 22,614.28 | 17,251.41 |
| APPLICATION OF FUNDS : | ||||||
| Gross Block | 24,462.96 | 23,447.77 | 18,593.32 | 15,943.09 | 13,613.33 | 12,441.26 |
| Less: Accumulated Depreciation | 9,659.15 | 8,952.24 | 7,569.63 | 5,411.00 | 4,239.75 | 3,044.79 |
| Less: Impairment of Assets | 9.62 | 2.74 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Block | 14,794.19 | 14,492.79 | 11,023.69 | 10,532.09 | 9,373.58 | 9,396.47 |
| Lease Adjustment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Work in Progress | 4,899.96 | 3,868.72 | 5,390.01 | 3,747.20 | 3,061.53 | 1,985.92 |
| Pre-operative Expenses pending | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Assets in transit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1,635.41 | 1,342.31 | 1,404.13 | 1,610.00 | 1,302.48 | 969.66 |
| Current Assets, Loans and Advances | ||||||
| Inventories | 10,543.72 | 9,808.23 | 8,511.23 | 7,553.85 | 9,026.57 | 7,699.87 |
| Sundry Debtors | 5,745.93 | 4,816.74 | 4,466.38 | 4,012.26 | 3,503.28 | 4,315.16 |
| Cash and Bank | 8,235.49 | 6,278.30 | 6,084.20 | 4,190.01 | 5,474.28 | 2,842.15 |
| Other Current Assets | 654.00 | 519.45 | 554.71 | 473.05 | 601.29 | 489.35 |
| Loans and Advances | 1,983.31 | 2,298.62 | 1,692.39 | 1,514.67 | 1,058.30 | 1,065.96 |
| Total Current Assets | 27,162.46 | 23,771.92 | 21,459.91 | 18,122.69 | 19,823.51 | 16,412.51 |
| Less : Current Liabilities and Provisions | ||||||
| Current Liabilities | 4,623.28 | 3,070.63 | 2,979.91 | 3,106.51 | 2,685.47 | 2,874.56 |
| Provisions | 560.49 | 505.80 | 412.13 | 228.59 | 382.29 | 511.72 |
| Total Current Liabilities | 14,682.34 | 12,199.13 | 11,493.78 | 8,155.98 | 10,665.15 | 11,384.64 |
| Net Current Assets | 12,480.12 | 11,572.79 | 9,966.13 | 9,966.71 | 9,158.36 | 5,027.87 |
| Miscellaneous Expenses not written off | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets by Liabilities | -989.69 | -856.08 | -287.88 | 122.37 | 121.88 | 128.49 |
| Total Assets | 34,799.36 | 32,515.82 | 28,006.60 | 25,354.78 | 22,614.28 | 17,251.41 |
| Contingent Liabilities | 368.26 | 311.34 | 158.53 | 157.74 | 140.83 | 145.98 |
SOURCES OF FUNDS
MAR 2025:-
MAR 2024:-
MAR 2023:-
MAR 2022:-
Share Capital
MAR 2025:58.08
MAR 2024:58.59
MAR 2023:58.59
MAR 2022:58.59
Share warrants and Outstandings
MAR 2025:0
MAR 2024:0
MAR 2023:0
MAR 2022:0
Total Reserve
MAR 2025:32,595.24
MAR 2024:29,784.21
MAR 2023:26,781.26
MAR 2022:24,517.39
Shareholder's Funds
MAR 2025:32,653.32
MAR 2024:29,842.8
MAR 2023:26,839.85
MAR 2022:24,575.98
Minority Interest
MAR 2025:-6.39
MAR 2024:8
MAR 2023:12
MAR 2022:-1.93
Secured Loans
MAR 2025:1,159.38
MAR 2024:2,134.9
MAR 2023:618.96
MAR 2022:249.21
Unsecured Loans
MAR 2025:402.27
MAR 2024:0
MAR 2023:0
MAR 2022:0
Total Debts
MAR 2025:7,941.68
MAR 2024:6,315.22
MAR 2023:4,861.52
MAR 2022:2,372.77
Total Liabilities
MAR 2025:34,799.36
MAR 2024:32,515.82
MAR 2023:28,006.6
MAR 2022:25,354.78
APPLICATION OF FUNDS :
MAR 2025:-
MAR 2024:-
MAR 2023:-
MAR 2022:-
Gross Block
MAR 2025:24,462.96
MAR 2024:23,447.77
MAR 2023:18,593.32
MAR 2022:15,943.09
Less: Accumulated Depreciation
MAR 2025:9,659.15
MAR 2024:8,952.24
MAR 2023:7,569.63
MAR 2022:5,411
Less: Impairment of Assets
MAR 2025:9.62
MAR 2024:2.74
MAR 2023:0
MAR 2022:0
Net Block
MAR 2025:14,794.19
MAR 2024:14,492.79
MAR 2023:11,023.69
MAR 2022:10,532.09
Lease Adjustment
MAR 2025:0
MAR 2024:0
MAR 2023:0
MAR 2022:0
Capital Work in Progress
MAR 2025:4,899.96
MAR 2024:3,868.72
MAR 2023:5,390.01
MAR 2022:3,747.2
Pre-operative Expenses pending
MAR 2025:0
MAR 2024:0
MAR 2023:0
MAR 2022:0
Assets in transit
MAR 2025:0
MAR 2024:0
MAR 2023:0
MAR 2022:0
Investments
MAR 2025:1,635.41
MAR 2024:1,342.31
MAR 2023:1,404.13
MAR 2022:1,610
Current Assets, Loans and Advances
MAR 2025:-
MAR 2024:-
MAR 2023:-
MAR 2022:-
Inventories
MAR 2025:10,543.72
MAR 2024:9,808.23
MAR 2023:8,511.23
MAR 2022:7,553.85
Sundry Debtors
MAR 2025:5,745.93
MAR 2024:4,816.74
MAR 2023:4,466.38
MAR 2022:4,012.26
Cash and Bank
MAR 2025:8,235.49
MAR 2024:6,278.3
MAR 2023:6,084.2
MAR 2022:4,190.01
Other Current Assets
MAR 2025:654
MAR 2024:519.45
MAR 2023:554.71
MAR 2022:473.05
Loans and Advances
MAR 2025:1,983.31
MAR 2024:2,298.62
MAR 2023:1,692.39
MAR 2022:1,514.67
Total Current Assets
MAR 2025:27,162.46
MAR 2024:23,771.92
MAR 2023:21,459.91
MAR 2022:18,122.69
Less : Current Liabilities and Provisions
MAR 2025:-
MAR 2024:-
MAR 2023:-
MAR 2022:-
Current Liabilities
MAR 2025:4,623.28
MAR 2024:3,070.63
MAR 2023:2,979.91
MAR 2022:3,106.51
Provisions
MAR 2025:560.49
MAR 2024:505.8
MAR 2023:412.13
MAR 2022:228.59
Total Current Liabilities
MAR 2025:14,682.34
MAR 2024:12,199.13
MAR 2023:11,493.78
MAR 2022:8,155.98
Net Current Assets
MAR 2025:12,480.12
MAR 2024:11,572.79
MAR 2023:9,966.13
MAR 2022:9,966.71
Miscellaneous Expenses not written off
MAR 2025:0
MAR 2024:0
MAR 2023:0
MAR 2022:0
Deferred Tax Assets by Liabilities
MAR 2025:-989.69
MAR 2024:-856.08
MAR 2023:-287.88
MAR 2022:122.37
Total Assets
MAR 2025:34,799.36
MAR 2024:32,515.82
MAR 2023:28,006.6
MAR 2022:25,354.78
Contingent Liabilities
MAR 2025:368.26
MAR 2024:311.34
MAR 2023:158.53
MAR 2022:157.74
FAQs
What are the Total Assets of Aurobindo Pharma in the recent year?
The total assets of Aurobindo Pharma in the most recent year are ₹34,799.36 crore. This is a cumulative figure comprising both current and non-current assets, representing resources that provide future economic benefits.
What is the Total Liability of Aurobindo Pharma in the recent financial year?
As per the latest financial reports, the total liabilities of Aurobindo Pharma in March 2025 are ₹34,799.36 crore. This figure represents the total amount owed by the company, including short-term and long-term obligations. While some liabilities are normal, increasing liabilities without corresponding growth in earnings and assets may indicate weak financial health.
What are the Contingent Liabilities of Aurobindo Pharma in the financial year 2025?
Aurobindo Pharma has accounted for ₹368.26 crore as contingent liabilities in the recent financial year. This indicates potential losses that may arise in the future due to specific uncertain events.
What is the Capital Work-in-Progress of Aurobindo Pharma in the financial year 2025?
In the financial year 2025, Aurobindo Pharma has ₹4,899.96 crore as Capital Work-in-Progress. This metric represents costs associated with assets that are under construction or development but not yet ready for their intended use.
Can I invest in Aurobindo Pharma shares with Anand Rathi?
Yes! If you are already registered with Anand Rathi, you can buy Aurobindo Pharma stocks through the TradeMobi Trading App or the Web Trading Platform.If you are new to Anand Rathi, follow these steps to open a demat account:
- Fill out the form with basic details.
- Upload the requested documents (ID proof, address proof, PAN card, and bank details) for verification.
- Complete the eKYC process online.
- Activate your account and start investing seamlessly through our trading app or web platform.